SEED Therapeutics Inc. has announced the appointment of Dr. Bill Desmarais, Ph.D., MBA, as Chief Financial Officer and Chief ...

Under the terms of the agreement, Alchemab will be taking the programme through early Phase 1 clinical trials after which Lilly will lead all further development and commercialisation. Alchemab's ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

For the past three decades, collaborations, deals and best practice exchanges on innovation and commercialisation have been a ...

Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly to develop and market ATLX-1282, a therapy candidate for amyotrophic lateral sclerosis (ALS) and other neurodegenerative ...

The collaboration began in July 2017 with a five-year agreement, where Lilly pledged up to $52m for life science research. Recently, Alchemab signed a licensing agreement valued at up to $415m with ...

Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and ...

Eli Lil­ly is set to pay up to $415 million in an ALS deal with Alchemab Therapeutics ... A federal judge sided with the FDA over its decision last year to remove Lilly’s GLP-1 drug tirzepatide from ...

Patricia Clarkson plays the equal pay activist Lilly Ledbetter in this misty-eyed drama. By Beatrice Loayza When you purchase a ticket for an independently reviewed film through our site ...

Under the terms of the agreement, Alchemab will be taking the programme through early phase 1 clinical trials after which Lilly will lead all further development and commercialisation. Alchemab’s ...